Presenter: PEJMAN KATIRAEI, DO

Title of Talk: Mycotoxins and Autism – The Missing Link

Abstract:

Children with autism have been found to have:

• 1) High oxidative stress
• 2) Metabolic and mitochondrial abnormalities
• 3) Elevated and abnormal maternal immune response during pregnancy
• 4) Abnormal systemic immunity with prevalence of mastocytosis
• 5) Abnormal mycobiomes, microbiomes and intestinal permeability
• 6) Gut immune activation with higher rates of inflammatory bowel disease
• 7) Microglial activation with resultant abnormalities in the amygdala and fear response
• 8) Abnormalities in neuroplasticity
• 9) Distortions in sensory pathways

According to the US EPA, 10-40% of US homes have mold (region dependent). A large body of scientific research can demonstrate that in-utero and early (first 2-3 years of life) exposure to molds and mold toxins may explain ALL of these abnormal physiological findings.

Very few parents have any awareness that there is mold in the home, and this exposure is often missed by practitioners. This presentation will demonstrate the above links and help practitioners understand why all children with autism should be screened for current or past mold exposure.

Presenter: NANCY O'HARA, MD, MPH, FAAP, FMAPS

Title of Talk: Demystifying Lyme & Co-Infections: Bringing It All Together: Testing and Pearls From the Day

Abstract:

Lyme disease and CO-infections, Borrelia, Bartonella, babesia and more are complex autoimmune diseases that require a multi-system approach. The presentation of these diseases can be chronic, subacute or acute as with PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome), and are among potential triggers for the immune dysregulation resulting in an abnormal autoimmune reaction and negative behavior, physical, and cognitive changes. Dr. O’Hara will discuss the latest research-guided testing in the assessment of these devastating but recoverable illnesses. She will also be pulling together all of the pearls that have been presented throughout the plenary session. Participants will learn the research-based functional medicine approach to the care, diagnosis and treatment of these children.

Presenter: ERICA PEIRSON, ND

Title of Talk: Person-First Medicine: Actionable Means to Support the Health and Development of Children with Genetic Conditions

Abstract:

Children with genetic conditions like Down syndrome, Noonan syndrome, Dup15q syndrome, DiGeorge syndrome and others frequently experience diagnostic overshadowing in the clinical setting. This tendency of clinicians to attribute all health problems to their genetic condition only, leaving other coexisting conditions undiagnosed and untreated greatly decreases their quality of life, increases their suffering and contributes to their higher mortality rate. Applying the same functional medical principles used to help children with autism, ADHD, PANDAS and other neurodevelopmental conditions with these children can uncover actionable health issues that, when treated, can significantly optimize their overall health and development. Imbalances in gut health, methylation, neurotransmitters, oxidative stress, micronutrient deficiencies, immune system and mitochondrial function have all been uncovered in these children in my practice and have improved with the right supplementation and diet changes. Case reports will be presented to share the remarkable stories of several children and how they benefited from looking beyond their genetics.

Presenter: DANA JOHNSON, PhD, MS

Title of Talk: Mind over motor: Understanding sensory motor differences and the impact of neurological "Noise" in the autistic population

Abstract:

Recent research on autism and movement differences point to neurological “noise” that impacts efficient and purposeful movement in the autistic population. These differences result in a disconnect between the brain and the body triggering the sympathetic nervous system and causing prolonged fight-or-flight responses. This presentation will discuss the current research on motor differences in autism including the sympathetic and parasympathetic responses to stress and how it applies to the nonspeaking and unreliably speaking autistic population. Specific ways to support the brain and body disconnect, regulation, and how to build purposeful motor skills including communication will be discussed. Nonspeakers who have contributed to the growing body of knowledge on motor differences and regulation will also be highlighted.

Presenter: JAMES NEUENSCHWANDER, MD, ABIM/AAPS, ABIHM, BCEM/AAPS, FMAPS

Title of Talk: HBOT and the Management of Chronic Infections

Abstract:

Hyperbaric oxygen therapy (HBOT) had originally been developed to treat decompression illnesses.  Since that time, multiple other indications for HBOT have emerged. Most of us are familiar with the uses of HBOT to manage localized infections that involve low oxygen states or with compromised blood flow. The classic examples of this would be gangrene and diabetic foot ulcers.  But what about using HBOT for systemic infections, both acute and chronic?  In this presentation, we will evaluate the mechanisms by which HBOT could be helpful for chronic infections.  In addition, we will examine the clinical evidence from the literature for efficacy of HBOT these situations. 

At the end of this lecture, participants should be well versed on the mechanisms of and evidence behind the use of HBOT for chronic infections like post treatment Lyme disease.

Presenter: SHANNON DELANEY, MD

Title of Talk: Neuropsychiatric symptoms related to lyme disease

Abstract:

In North America, Lyme disease (LD) is primarily caused by the spirochetal bacterium Borrelia burgdorferi, transmitted to humans by Ixodes species tick bites, at an estimated rate of 476,000 patients diagnosed per year.   Most acute cases of Lyme disease are effectively treated with antibiotics, but 10-20% of individuals may experience recurrent or persistent symptoms. Children may present with severe neuropsychiatric symptoms such as new onset OCD, anorexia, depression, anxiety or other sensory or behavioral problems; this condition is termed Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). This lecture focuses on the neuropsychiatric aspects of Lyme disease, as these are less widely recognized by physicians and often overlooked. Additionally, new tickborne illnesses are emerging, such as Borrelia miyamotoi; clinical data regarding this disease will be discussed. Broader education about the potential complexity, severity, and diverse manifestations of Lyme disease and other tick-borne diseases is needed.

Presenter: THEOHARIS C. THEOHARIDES, BA, MS, MPhil, PhD, MD, FAAAAI

Title of Talk: Brain mast cells and microglia lead to neuroinflammation and disrupt neuronal communication

Abstract:

Many large epidemiological studies have reported a strong association between Autism spectrum disorder (ASD) and atopic or neuroinflammatory conditions that involve the unique immune cells, mast cells and microglia. Using brains of deceased male children with ASD (n=7) and normal male children (3-14 yrs old) from the NIH NeuroBioBank, we had reported increased expression of the proinflammatory cytokine IL-1β and decreased levels of anti-inflammatory cytokine IL-38 in the amygdala, which are essential for our ability to feel emotions, sense fear and regulate behavior. We had also shown elevated levels of neurotensin, which stimulated cultured human microglia to secrete IL-1β We recently showed that the hippocampus, which is critical in social memory, had increased number of activated mast cells and microglia that contained and secreted large amounts of metalloproteinase-9 (MMP-9), which degrades chondroitin sulphate proteoglycans (CSPGs), a family of extracellular matrix molecules that serve as a key link between neurodevelopment and synaptic plasticity. We also conducted RNAseq profiling on postmortem human hippocampus and identified molecular pathways involved in extracellular matrix organization, neurodevelopment, synaptic regulation, and immune system signaling. We used qRT-PCR and Western blotting and confirmed increased expression of MMP9, but decreased expression of synaptic proteins PSD95, SYN1 and MEF2C. Our results point to alterations in immune system signaling, extracellular matrix molecule expression, microglia activation and expression of genes implicated in synaptic signaling and in ASD including SYN1 and MEF2C. Future studies will attempt to correlate such findings with ASD subtype and/or severity of symptoms to identify subgroups that may be amenable to targeted treatment approaches. Preliminary results indicate the ability of the natural flavonoid luteolin, which we had reported inhibits release of IL-1β from both mast cells and microglia, to also inhibit secretion of MMP9. Luteolin has been formulated in in softgel capsules with olive pomace oil for improved oral absorption (e.g. NeuroProtek®, NeuroProtek-Low Phenol) and in NeuroProtek-Low Phenol Liquid® that can be administered with a dropper under the tongue.

Presenter: HEATHER TALLMAN RUHM, MD

Title of Talk: Total Body Load in Childhood Illness: A Higher-Order Systems Approach

Abstract:

Children’s lives reflect a perfect storm of events and exposures, past and present. The quality of our answers for addressing their needs reflect the quality of questions asked and “90% is in the history.” A deep look reveals varied networks of interdependent biologic systems - cells, tissues, pathways, organs, organelles andorganisms with dynamic roles and relationships – all influenced by the Total Body Load acquired in the modern world. Each child presents a developmental continuum with a unique profile – milestones met, missed, at risk of being missed, or in need of repair. None of us can be expert at every modality, test, interpretation, environmental factor, or the latest scientific understanding (or sort out all the misconceptions). CHIRP(TM) and FLIGHT(TM) are two on-going IRB approved research studies with a broad array of data, an “embarrassment of riches,” that allows us to document the complexity that today’s child presents and work toward a simplified collaborative model that results in Genuine Health Transformations (the GHT in FLIGHT). Using a large magnifying glass on a small sample size has already generated surprising insights and tools for clinical decision making. This presentation will provide a look at some of the early findings and how they might benefit an astute clinician.

Presenter: THOMAS A. MOORCROFT, DO

Title of Talk: Cutting edge treatments for lyme and co-infections in pediatrics

Abstract:

Lyme disease and tick-borne co-infections are becoming increasingly appreciated as causes of human disease and morbidity as well as triggers for Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS/PANDAS. Once thought to be relatively rare, researchers are now finding that co-infection of ticks, such as Ixodes scapularis, occurs "more frequently than expected, resulting in enhanced human exposure to multiple infections that can cause more severe symptoms and sometimes make diagnosis more difficult" [Dunn 2014]. This knowledge has helped clinicians better define the often complex presentation of pediatric patients with acute onset behavioral changes and persistent tick-borne disease and opened new pathways for effective treatment and management of these patients.

Along with this greater understanding of the frequency of tick co-infection, other researchers have also looked for more effective treatment approaches for persistent co-infections. In this lecture, Dr. Moorcroft will review recent research breakthroughs and clinical applications in the utilization of both pharmacologic and botanical antimicrobials that have led to significant improvements in patient outcomes, decreased patient suffering and decreased burden of illness to society.

Presenter: THOMAS A. MOORCROFT, DO

Title of Talk: Utilizing methylene blue within chronic infections

Abstract:

Methylene blue, the first fully human-made medicine, was used as far back as 1891 as an anti-malarial drug. After falling out of favor due to side effects, such as blue urine and sclera, its use as an anti-malarial waned, religating its use to the treatment of methemoglobinemia and as a medical dye.

Interest in methylene blue has been revived in the past 20 years. It is a potent antioxidant, which has led to great interest in its potential uses in increasing longevity, making it a commonly discussed medication in the biohacking community. Known to have antiparasitic, antiviral and antibacterial properties, researchers have begun looking into its use in many infections, including viruses, Lyme disease and Bartonellosis.

In this lecture, Dr. Moorcroft will review the pharmacology of methylene blue and known applications as an antioxidant and antimicrobial. Specific focus will be placed upon the research and clinical use of this medication in addressing persister forms of infections, including Bartonella henselae. Having extensively used this medication in combination with both pharmaceutical and herbal antimicrobials in both adult and pediatric patients, Dr. Moorcroft will share clinical pearls for determining which patients are likely to respond best and how to most effectively combine this drug with other treatments for optimal patient outcomes.

Presenter: VIKKI KOBLINER, MS RDN, FMAPS

Title of Talk: FOUNDATIONS OF NUTRITION IN PEDIATRICS

Abstract:

Nutrition is the cornerstone of growth and development for all children, healthy or ill. Every biochemical pathway relies on vitamins, minerals, amino acids, fats, and other essential cofactors. Chronic illness depletes these nutrients, while underlying dysfunction in digestion and absorption can further widen the gap between nutrient needs and intake. For a child with any chronic illness the lack of critical nutrients can have far-reaching effects, particularly in the areas of neurocognitive, immune and mitochondrial function, as well as inflammation, detoxification and methylation. This lecture is an essential primer for identifying tell-tale signs of nutritional deficiencies, using therapeutic nutrition for healing, and understanding various dietary approaches that we use in integrative pediatrics.

Presenter: TAYLOR BEAN, ND, FMAPS

Title of Talk: Vaccine Optimization in the 21st Century (Part ll)

Short Description

I am passionate about providing accurate information within the conversations surrounding vaccines. I feel strongly about access to accurate, transparent information because anything less, compromises our movement towards best practices for infants, adults and elderly population.

Abstract:

The concern and questions around vaccines is growing substantially around the globe. With this comes a lot of fear and concern about infections, vaccines, choices, traveling abroad and simply not being fully informed before making a decision around vaccinations. As one of very few ND’s in British Columbia, Canada to have obtained the Immunization Certification, Dr. Bean would like to present on some key areas around vaccinations that we as practitioners should know and what we can provide for our patients when they have questions. This should not be a topic of fear or anger but a topic that is honest, forthcoming and transparent.

As a continuation from her presentation at Spring MAPS 2023 conference, Dr. Bean will be diving deeper into vaccine solutions. She will be highlighting the potential adverse reactions listed by the British Columbia CDC Adverse reporting system along with the CDC and present how to support the body to prevent these potential adverse reactions, support post vaccination along with post surveillance reactions.

Presenter: LIZ MUMPER, MD, FAAP FMAPS

Title of Talk: Practical experience on the prevention of autism

Abstract:

Can awareness of medical problems common in autism and emerging data about pathologic pathways in autism lead to prevention of some autism cases? This is the question Dr. Mumper asked in 2005, which lead to an ongoing autism prevention project at Advocates for Children, her general pediatric primary care practice. After 16 years of data collection, the answer seems to be "yes."

In this lecture, Dr. Mumper will discuss how the medical abnormalities seen in patients with autism informed practice recommendations to families born into her practice. She will discuss why it became a priority at Advocates for Children to promote optimal gut flora diversity in the first thousand days of life. She will discuss how optimal Vitamin D recommendations, promotion of prolonged breastfeeding, limitation of antibiotic prescriptions, constraints on acetaminophen use, and use of a modified vaccine schedule may have impacted lower rates of autism, ear infections, allergies and developmental delays seen in her practice compared to background rates.

Presenter: MYRIAH HINCHEY, ND

Presentation Title: The Interplay Between COVID and Lyme

Research Focus: Key similarities and discrepancies in the diagnosis and management of SARS-CoV-2 and Borrelia

Abstract:

The COVID pandemic has greatly impacted the way medical professionals have encountered and can assess Lyme disease and tick-borne illness (TBI) over the past three years. Because of the hyperfocus on SARS-CoV-2 and its variants, many severe illnesses have gone undiagnosed and mismanaged. This has led to a greater incidence of complications from these TBI1, creating a silent pandemic of chronic infectious illness. Not only are those recently infected with Borrelia bugdorferi at a higher risk of being undiagnosed in a timely manner, the infection itself presents a greater risk for complications of SARS-CoV-2, should they also become infected with COVID. Newer research is finding that increased levels of Borrelia-specific IgG correlate with greater severity of COVID symptoms and increased risk of hospitalization.2 The link between Borrelia and SARS-CoV-2 is becoming increasingly apparent, and this lecture aims to shed light on the precise mechanisms of action these two infectious agents affect.

Cytokine pathways altered by Lyme disease are well documented34, and are nearly identical to those affected by COVID infection. A significant increase in the expression of the following biomarkers is noted in both Lyme and COVID patients: ACE-2, AKT-1, CD44v6, IL-4, MMP-9, α-SMA, Sphingosine-1, and TGF-β15. Practitioners familiar with anti-inflammatory and immune modulating protocols may have success addressing these pathways for patients experiencing exacerbations of symptoms of Lyme, COVID, or both.

Presenter: RICHARD FRYE MD, PHD, FMAPS

Presentation Title: ENVIRONMENTAL INFLUENCES ON MITOCHONDRIAL FUNCTION: A NEURODEVELOPMENTAL PERSPECTIVE

Abstract:

Accumulating evidence suggests that many neurodevelopmental disorders involve dysfunction of the mitochondria. Several factors associated with neurodevelopmental disorders, including toxins, nutrients and inflammation can affect metabolism, particularly the mitochondria, resulting in mitochondrial dysfunction, oxidative stress and immune dysregulation that may be long lasting. These processes appear to start prenatally and continue well into childhood. Many times, these effects may be subclinical and may not be obvious in infancy and may predispose children to neurodevelopmental regression resulting from an external toxin or inflammatory trigger. On the other side, many prenatal factors can decrease the risk of neurodevelopmental disorders or provide resilience. For example, prenatal nutrients, such folate, can reduce the risk of neurodevelopmental disorders when supplemented and other prenatal nutrients such as folate, vitamin D and zinc can increase the risk of neurodevelopmental disorders when deficient. These nutrients can directly influence mitochondrial function. Additionally, the microbiome, which we understand is of increased importance in health, can also modulate mitochondrial health, potentially starting prenatally and extending well into childhood and adult life. The mechanism in which the mitochondrial can influence neurodevelopment and brain function extends from prenatal brain development, where the mitochondria may be critical in modulating the development of brain architecture, to childhood, where mitochondria have a critical role in both inhibitory GABAergic neuronal function and excitatory glutamate metabolism. The evidence for these abnormalities and potential methods for intervention will be discussed.

Presenter: MYRIAH HINCHEY, ND

Presentation Title: A deep dive into the pathophysiology of Borreliosis and Babesiosis and the MOAs of Herbal Intervention.

Abstract:

The field of tick-borne disease (TBD) is complex and ever-evolving. With recent research providing measurable evidence of how Herbal and Naturopathic medical interventions impact the initial infection and progression of TBD, functional medicine clinicians have a tremendous opportunity to change the course of a patient’s journey with Lyme disease and co-infections through individualized care in both the acute and chronic stages of illness. This lecture is an overview of the pathophysiology of Lyme disease causing species of Borrelia as well as Babesia. It includes a deep dive into the biochemical pathways involved in both acute and chronic infection, understanding the mechanism of action (MOA) of studied herbal interventions, a four-pronged approach to treatment, and naturopathic interventions to support healing at every step.

A complex network of functional deficiencies needs to be addressed to prepare each patient for an optimal therapeutic response to a tick-borne infection. Individual constitution, genetics, nutrient deficiencies, gastrointestinal dysbiosis, food sensitivities, heavy metal and toxin burden, immune imbalance, mycotoxin illness, endocrine dysfunction, as well as pre-existing biofilm status, contributes to an inflammatory milieu, which provides a safe harbor for infections. A major obstacle to achieving treatment success is the suppressive effect of inflammation on critical functions, including immunity. Research is providing a more in-depth understanding of the mechanisms driving chronic inflammation, pointing to new therapeutic targets and interventions.

Substantial evidence points to galectin-3 (Gal-3), a carbohydrate binding protein, as an important signaling molecule triggering proinflammatory and profibrotic pathways relevant in tick-borne illness. Though Gal-3 plays an essential role in the body’s initial recognition and response to infection, at elevated levels, it fuels chronic inflammation, fibrosis, and immune suppression. Gal-3 forms an adhesive framework for biofilm formation via its ability to form “lattice/scaffolding” structures by self-polymerizing and crosslinking to glycoproteins and glycolipids. It binds with immune cell surface receptors and antigenic sites on infectious agents, interrupting the communication and activation of critical immune responses and immune surveillance. Gal-3 also interacts with pathogenic organisms to enable adhesion and penetration within tissues to establish biofilms. Research shows that a natural Gal-3 inhibitor, modified citrus pectin, disables Gal-3-orchestrated immune suppression and stimulates NK cell production, enabling a robust immune response while controlling inflammation.

Successful antimicrobial interventions require preparation to strengthen and support the body’s innate detoxification systems, correct deficiencies, and create a pathogen-resistant environment, all of which promotes a balanced and robust immune response. Additionally, it is imperative to understand the pathophysiological process in which the organisms hijack the immune system allowing them not only to survive, but thrive while ravishing the human body. Once a practitioner has an understanding of this process, along with understanding the mechanism of action of each herb, it is easy to put together an intelligent treatment protocol to intervene at each pathophysiological process and begin to heal the body from TBD while killing the organisms. In this presentation, Myriah Hinchey, N.D., a recognized clinician with success in treating complex chronic tick-borne illnesses for over a decade, will present her multilayered approach to individualized treatment.

Learning Objectives & Lecture Schedule

• Why many treatments fail (1 min)
  • Shifting focus from just killing pathogens to making the body inhospitable to infection and healing the patient
• Understanding the pathophysiology of Lyme infection (20 minutes)
  • Transmission of infection
  • Acute infection
  • Chronic infection
  • MOA of herbs and how they intervene
• How co-infections differ (10 minutes)
  • Babesia pathophysiology
• A comprehensive approach to treatment (12 minutes)
  • Decrease inflammation: restore GI integrity
  • Restore immune function: protect RBCs and increase nitric oxide
  • Detoxify: naturopathic supportive therapies
  • Kill the pathogen: herbal antibiotics
• The role of Gal-3 in Lyme infection (3 minutes)
• Modified citrus pectin: natural Gal-3 inhibitor and comprehensive Lyme intervention (5 minutes)
• Pediatric Case studies (5 mins)

Presenter: TERESA HOLLER, MS, PA-C

Presentation Title: Addressing Lyme in Your Practice

Abstract:

This presentation is designed to be a stand-alone tool for practitioners to confidently initiate effective treatment for PANS/PANDAS and Lyme borreliosis. Case studies will be utilized to present the data in an easy-to-digest manner, and participants will leave the presentation with the knowledge of a simple, safe, and effective treatment option that they can implement immediately in their practice.

Upon completion of Teresa Holler's presentation, participants will achieve the following:

• Awareness of recent studies confirming a link between PANS/PANDAS and Lyme borreliosis
• Understanding of the pleomorphic nature of Lyme borrelia
• Awareness of clinical studies comparing the antibiotic doxycycline to herbal products
• Understanding of the effectiveness of both prescription and herbal antimicrobials on persister forms of Lyme borrelia

Presenter: NANCY O'HARA, MD, MPH, FAAP, FMAPS

Presentation Title: Demystifying PANS/PANDAS: A Functional Medicine Guide on Basal Ganglia Encephalitis

Abstract:

PANS & PANDAS are complex autoimmune diseases that require a multi-system approach. PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Strep) involves antibodies from a strep infection reacting with brain tissue (specifically the basal ganglia in the brain) and triggering an abrupt onset of immune dysregulation and movement, learning and behavioral problems including OCD, anxiety and tics. With PANS (Pediatric Acute-Onset Neuropsychiatric Syndrome), other infectious etiologies besides strep (yeast, viruses, other bacteria, parasites), toxic exposures, and metabolic abnormalities are among other potential triggers for the immune dysregulation resulting in an abnormal autoimmune reaction and negative behavior, physical, and cognitive changes. Dr. O’Hara will discuss the latest research in the assessment and treatment of these devastating but recoverable illnesses in the context of several illustrative case studies.  Participants will learn the research-based functional medicine approach to the care, diagnosis and treatment of these children.

• The participant will be able to understand the assessment, diagnosis and treatment of PANS, PANDAS and Basal Ganglia Encephalitis through Case Study presentations
• The participant will be able to differentiate causes of anxiety, OCD and tics, as it relates to autoimmune encephalitis.
• The participant will be able to define the triad of treatments for PANS and PANDAS.

Presenter: DARIN INGELS, ND, FAAEM, FMAPS

Presentation Title: Low dose immunotherapy: A Novel Treatment for Tick-Borne Disease

Abstract:

Lyme disease and coinfections can often trigger autoimmune reactions that can cause gastrointestinal, neurological and connective tissue disorders. Few therapies exist to modulate the immune response and downregulate overexpression toward autoimmunity. Low dose immunotherapy (LDI) is a novel new approach to accomplish that goal. LDI is a nosode therapy that evolved from low dose allergy therapy (LDA), developed by Dr. Len McKewen more than 60 years ago. Dr. Ty Vincent developed LDI almost 9 years ago after recognizing that the immune mechanisms involved with allergies was not dissimilar to how the immune system reacted to various microbes. Research shows that microbes, including Lyme, can upregulate Th2 pathways and produce antibodies that cross-react with several proteins on our cell surfaces causing inflammation and symptoms. LDI utilizes diluted inactivated organisms mixed with beta glucuronidase to help modulate Treg cells and downregulate Th2 activity. Patient symptoms often improve after using LDI. LDI is a novel therapy to help modulate autoimmune mechanism triggered by Lyme or coinfections. Other conventional immune modulating therapies, such as IVIG are difficult to get insurance reimbursement, expensive and come with potential risks and side effects. There are currently no other oral treatments that specifically address microbe-induced autoimmunity. This safe, cost-effective therapy can be used with any Lyme patient, regardless of age or health condition.

Objectives:

• Be able to describe the underlying mechanisms of LDI and how it influences the immune system
• Recognize which pathogens are associated with specific autoimmune diseases
• Be able to manage patient responses to LDI and make appropriate adjustments to treatment

Presenter: DARIN INGELS, ND, FAAEM, FMAPS

Presentation Title: Natural Treatment of Common Childhood Infections

Abstract:

Acute and chronic infections are common reasons children are brought to see their pediatrician as well as visits to the emergency department. In this lecture, Dr. Ingels will explore the underlying etiology of what factors precipitate these infections, including otitis media, sinusitis, urinary tract infections, bronchitis, diarrhea, impetigo and MRSA. Several nutritional and herbal therapies can be utilized to help support the child’s immune system and fight infection without the same risks of conventional antibiotic therapy. Dr. Ingels will review how to manage underlying foundational terrain disruptors and specific treatments for each type of infection.

Objectives:

• Be able to describe root causes of acute and chronic infections.
• Identify natural treatments appropriate for each type of infection and proper dosing.
• Understand contraindications for nutritional and herbal therapies and when referral is appropriate.

Presenter: LIZ MUMPER, MD, FAAP FMAPS

Case Presentations

Abstract:

In a series of 3 cases, Dr. Mumper will demonstrate how the use of innovative medical interventions lead to clinical success in two of the cases. In the third case, brain surgery to remove seizure foci was considered because classic treatments had failed to adequately control the patient’s seizures.

The first case will explore the clinical indications and specifics of antifungal therapy to impact behavior in children with autism, especially for self-injurious behavior. The second case explores the successful use of amantadine for obsessive compulsive behaviors. The third case is the patient that motivated Dr. Mumper to leave her academic position as Director of Pediatric Education at a family practice residency program to start a solo practice to address the needs of children affected by the autism epidemic. The patient regressed into autism after his 15-month check-up. Despite Dr. Mumper’s best efforts to apply emerging science to his neurodevelopmental problems over the past 22 years, he has little language today and his seizures are challenging to control.

Presenter: AUNNA HERBST, ND, DO

Presentation Title: PDD, ODD and Bedwetting - Utilizing Genomics as a guide for direct care and successful outcomes:

Abstract:

Epigenetics and genetics go hand in hand. Our various proteins and enzymes are determined by our genetics -which relates to our metabolic needs. Epigenetics means "on top of genetics" and relates to how we can modulate the genetic code we are born with and how our interactions with our world affect our genetic expression. This lecture will demonstrate, by case review, how utilization of targeted genomic information can help individualize treatment and improve outcomes. Talk will be reference-based, and will focus on clinical treatments from the lens of a primary care, functional medicine, physician, and will be accessible to both experienced and novice healthcare providers.

Presenter: LINDSEY WELLS, ND, FMAPS

Presentation Title: Best herbals for lyme and lyme co-infections

Abstract:

It is estimated that about a third of patients treated for Lyme Disease with antibiotics per CDC guidelines continue to experience persistent symptoms post treatment. There are many reasons as to why this may occur, including the limitation of antibiotics to effectively eradicate these infections. This lecture will highlight the importance of including botanical herbs in treatment protocols due to their potent antimicrobial actions against various morphological forms, ability to support the immune system, and improve symptoms. Various herbals will be discussed in detail so one will feel confident implementing herbs for more successful treatment outcomes in clinical practice.

Presenter: MARIA GAHRY, DNP, RN, FNP, FMAPS

Title of Talk: BIOCHEMICAL BASIS OF THE INTEGRATIVE APPROACH

Abstract:

Buckle up! This presentation is a 60 minute foray into the biochemistry behind the integrative/biomedical approach. We will cover the basics of methylation and the methylation/sulfation connection. The principles and importance of the gut-brain-immune triad. The impact of gut health on the entirety of health. We will dive into mitochondrial function (it is far more than the powerhouse of the cell) and the importance of the cell danger response. Finally, we will look at the impact of toxins on the function of our kids’ physiology. By the time we are done, you will have a firm grasp of the biochemical basis of the biomedical approach.

Presenter: MICHAEL ELICE, MD, FMAPS

Title of Talk: ASSESSMENT IN CLINICAL PEDIATRICS

Abstract:

In this 45 minute, we will evaluate the sometimes confusing landscape of assessing the kids we see. What are the advantages of the various tests commonly used by integrative practitioners? How can we more efficiently use our traditional labs? What are some of the shortcomings of some of our integrative tests and how do we most efficiently use our client’s resources to get the information we need.

Presenter: JAMES NEUENSCHWANDER, MD, ABIM/AAPS, ABIHM, BCEM/AAPS, FMAPS

Title of Talk: FOUNDATIONS OF BIOMEDICAL THINKING

Abstract:

Frequently, we are not aware of our thought process; and this can get in the way of appropriately managing our patients. In this presentation, we will identify the key differences in the thought process behind the biomedical approach versus our standard medical model. Understanding the interconnectedness of our systems and how manipulating one thing in one system can impact the entire body. We will investigate how to change the thought process when we approach our patients. As Dr. Sid Baker once said, “if you are having problems answering a question about how to treat a patient, maybe you are asking the wrong question.”

Presenter: DAN ROSSIGNOL, MD, FAAFP, FMAPS

Title of Talk: A review of new research findings in autism spectrum disorders

Abstract:

Dr. Rossignol will present recent studies that have been published in the last year on autism. From over 10,000 published articles, the most relevant studies will be discussed. The reviewed studies include medical comorbidities of autism, diets, IVIG, and new treatments including nutritional supplements and medications.

Presenter: DANE FLIEDNER, M.D., MPH, FAAP, IFMCP, FMAPS, ABOIHM

CASE PRESENTATIONS

Abstract:

"Although the rates of neurodevelopmental disorders has grown exponentially over the last decades, there is another, more insidious and often more devastating group of conditions that are becoming increasingly prevalent. Neuroimmunologic disorders have exploded in frequency, especially in light of Covid-19’s long term sequelae. These cases will highlight some of the disparate presentations of neuro-immune disorders, along with some discussion of commonly associated comorbidities seen in this group of patients."

Presenter: DAVID DORNFELD, DO, FMAPS

CASE PRESENTATIONS

Abstract:

When looking at ways to help children and adults with Autism Spectrum disorders, one needs to look at the environmental triggers and how it influences outcomes and may delay progress of the children. It is my hope to be able to demonstrate through two or three of my patient cases, a logical pathway of evaluating patients with PANDAS, PANS, Babesia with lyme disease and Crohn's disease, and help return the child to a more neuro-typical presentation. I try to utilize detoxification and hyperbaric therapies when needed in many of my ASD patients and will share these techniques and I review these cases.

Presenter: RICHARD BOLES, MD

Title of Talk: Genetic Testing in Autism Results in Diagnoses in Two-Thirds of Cases and Treatment Options in Most

Abstract:

Abstract authors: Omri Bar¹, Elizabeth Vahey¹, Mark Mintz¹, Richard G Boles^1,2
1Neurabilities Healthcare, Voorhees, NJ
²NeuroNeeds, Old Lyme, CT

OBJECTIVE: To determine the current sensitivity of trio whole genome sequencing (trio-WGS) in autism, as the last decade has seen dramatic improvements in the proportion of the genome clinically sequenced (e.g., < 1% to > 99%), accuracy, bioinformatic tools, and variant databases. Additionally, the current literature is almost entirely from academic research centers, with essentially no contribution from independent/private physician providers. METHODS: NeurAbilities Healthcare® is an independent organization specializing in neurodevelopmental disorders. As part of our routine clinical practice, we analyzed the raw DNA sequencing files on the Variantyx® (Framingham, MA) bioinformatics platform for the last 50 autism patients with trio-WGS.

METHODS: NeurAbilities Healthcare^® is an independent organization specializing in neurodevelopmental disorders. As part of our routine clinical practice, we analyzed the raw DNA sequencing files on the Variantyx^® (Framingham, MA) bioinformatics platform for the last 50 autism patients with trio-WGS.

RESULTS: Primary Diagnostic Variants (PDVs; meaning one gene contributes the bulk of genetic causation) were provided in 34/50 (68%) of cases, including 25 (50%) heterozygous de novo, 3 X-linked, 4 autosomal recessive, 2 autosomal dominant (affected parent), and 1 heteroplasmic maternal (mtDNA, one also has a de novo). All variants considered for PDVs were “Qualified”, defined as coding (changing the amino acid code), very rare, and evolutionarily conserved; in addition to published data linking that gene to autism. De novo variants in genes associated with autism were far more likely to be Qualified than non-Qualified (control group, P=0.002, validating that most Qualifying variants are indeed disease causal). Only 14/34 (41%) of PDV cases had the variant listed on the laboratory report. The “missed” cases predominately included genes with zero (novel etiologies in 14 cases) to ≤5 prior reported case reports. Many cases both with and without a PDV had inherited Qualifying variants in known autism-associated genes, suggesting polygenic inheritance. Thirty-three participants (66%) had treatment recommendation(s) based on DNA analyses, with a substantial proportion demonstrating anecdotal clinical improvement on this treatment; data analysis is ongoing.

CONCLUSIONS: Our results demonstrate high yield of trio-WGS for revealing molecular diagnoses in autism that is greatly enhanced by re-analyzing DNA sequencing files. Many are de novo and represent un/under-published conditions. The pathways represented by these genes contribute to understanding genetic vulnerability to develop autism.

FUNCTIONAL-MAPS IMPLICATIONS: Scientific advances and clinical observation strongly suggest that autism is the result of a complex interaction between genetic predisposition and environmental triggers. Therapy is best attempted following a robust, personalized work-up for both. Based on the functions of the genes involved, many of the pathways are treatable, including cation transport, redox state/energy metabolism, amino acids, and neurotransmission.

Presenter: HEATHER WAY, PhD

Title of Talk: A ROADMAP TO AUTISM RECOVERY: A MULTIFACETED APPROACH.

Abstract:

Dr. Way will discuss how cutting-edge genomic technologies can be used to assess susceptibility to various toxins and improve the outcomes for children with ADHD and Autism. The mechanisms by which genetic predispositions and gut dysbiosis contribute to toxicity, inflammation, oxidative stress, speech issues, and attention and focus will be examined. Case studies will demonstrate how we use microbiome sequencing and specialist nutrigenomics to ascertain which detoxification pathways might be inhibited, including those dealing with environmental toxins, heavy metals, pollution, pesticides, vaccines, and other pharmaceuticals. Gene expression can then be modulated without drugs using nutrition and natural supplements. Attendees will also learn about the use of probiotics to enhance detoxification capacity, rebuild the microbiome, restore cognition and ameliorate many other ASD and ADHD symptoms.

Presenter: MICHAEL SCHRANTZ, CIEC, CMI, BPI-BA/EP

Title of Talk: FUNDAMENTALS OF ENVIRONMENTAL MOLD ASSESSMENT AND REMEDIATION

Abstract:

• Present fundamentals regarding comprehensive mold assessments & sampling for those with chronic illness
• Discuss various limitations with typical mold assessment & sampling techniques
• Identify best practices for mold remediation & environmental-cleaning

There is a general lack of knowledge in the consumer and professional sectors regarding how a comprehensive mold assessment can help patients identify exposures in their occupied spaces. Such assessments vary significantly from a typical mold assessment that too often will miss exposures that clinicians are seeing with their patients. Education regarding these concerns, and resources to help both the patient and clinician are considered key learning objectives.

Presenter: TERESA HOLLER, MS PA-C

Title of Talk: ADDRESSING MOLD AND MYCOTOXINS IN THE PANS/PANDAS PATIENT

Abstract:

This presentation is designed to be a stand-alone tool for practitioners to confidently initiate effective treatment for Mold and Mycotoxin illness in patients with PANS/PANDAS.

Case studies will be utilized to present the data in an easy-to-digest manner, and participants will leave the presentation with the knowledge of a simple, safe, and effective treatment option that they can implement immediately in their practice.

Upon completion of Teresa Holler's presentation, participants will achieve the following:

• Awareness of recent studies confirming a link between PANS/PANDAS and Mold/Mycotoxins and the need to look beyond infectious triggers of PANS/PANDAS
• Understand the toxicity associated with certain mycotoxins (i.e mycophenolic acid as an immunosuppressant)
• The Ability to Manage Mast Cell Activation, which is often triggered by Mold and Mycotoxin illnesses.
• Understanding of how to use prescription and/or natural anti-inflammatories, binders, antifungals and other antimicrobials, and other treatments in the management of the patient with PANS/PANDAS with concurrent mold and mycotoxin illness

Presenter: TERESA HOLLER, MS PA-C

Title of Talk: ADDRESSING MOLD AND MYCOTOXINS IN THE PANS/PANDAS PATIENT

Abstract:

This presentation is designed to be a stand-alone tool for practitioners to confidently initiate effective treatment for Mold and Mycotoxin illness in patients with PANS/PANDAS.

Case studies will be utilized to present the data in an easy-to-digest manner, and participants will leave the presentation with the knowledge of a simple, safe, and effective treatment option that they can implement immediately in their practice. 

Upon completion of Teresa Holler's presentation, participants will achieve the following:

•  Awareness of recent studies confirming a link between PANS/PANDAS and Mold/Mycotoxins and the need to look beyond infectious triggers of PANS/PANDAS
• Understand the toxicity associated with certain mycotoxins (i.e mycophenolic acid as an immunosuppressant)
• The Ability to Manage Mast Cell Activation, which is often triggered by Mold and Mycotoxin illnesses.
• Understanding of how to use prescription and/or natural anti-inflammatories, binders, antifungals and other antimicrobials, and other treatments in the management of the patient with PANS/PANDAS with concurrent mold and mycotoxin illness

Presenter: ARISTO VOJDANI, PHD

Title of Talk: THE TOXISOME

Abstract:

Long COVID in Children and Adults: Major Findings, Mechanisms and Recommendations

A novel syndrome called long-haul COVID or long COVID is increasingly recognized in a significant percentage of individuals within a few months after infection with SARS-CoV-2. This disorder is characterized by a wide range of persisting, returning or even new but related symptoms that involve different tissues and organs, including respiratory, cardiac, vascular, gastrointestinal, musculo-skeletal, neurological, endocrine and systemic. Some overlapping symptomatologies exist between long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Very much like with long ME/CFS, infections with herpes family viruses, immune dysregulation, and persistence of inflammation have been reported as the most common pattern for the development of long COVID. This presentation is based on my own research and articles published in the past two years.

Our major objectives are to describe

• COVID-19 and its relationship to autoimmunity
• Neurodevelopmental problems in infants from mothers who had COVID-19 while pregnant
• Risk factors, mechanisms and effects of long COVID in children and adults
• Available laboratory testing for early detection of long COVID
• Based on test results, what action should be taken to manage long COVID and prevent lifelong disabilities?

Presenter: SHARON HAUSMAN-COHEN, MD

Title of Talk: GENETIC SUSCEPTIBILITY TO TOXICANTS AND AUTISM

Abstract:

How genetic susceptibility to toxicants can contribute to ASD and how to address these susceptibilities in a targeted manor.   In this talk gene variants of PON1, GSTM1/GSTP1 deletions, as well as discuss variants in the γ-glutamyl cycle (synthetic pathway for glutathione) and how they have been shown to contribute to autism. It will then be discussed how to address these variants when present in a genomically targeted fashion with interventions that have been demonstrated to have benefit in children with ASD.

Presenter: DEBBY HAMILTON, MD, MPH

Title of Talk: GLYPHOSATE: THE NEXT AGENT ORANGE AND HOW IT IS IMPACTING OUR CHILDREN

Abstract:

Glyphosate is an herbicide first used in the 1970’s with an increase in use of over 100% in the past 50 years. The greatest increase has been in the last 10 years. Initially glyphosate was thought to be inactive in humans because it disrupts the shikimate pathway that is absent in all mammals. The problem with this thinking is that humans contain a large microbiome throughout the body that contains billions of bacteria which do have the shikimate pathway. Glyphosate therefore selectively harms specific strains of microbial bacteria leading to an imbalanced microbiome. Since we know the microbiome has a large impact on the immune system along with being a critical part of the gut-brain-microbiome axis, glyphosate has the ability to negatively impact health throughout the body. In addition, glyphosate exposure in pregnancy could have severe long-term effects on development of the nervous system and the microbiome of infants. Animal studies with glyphosate exposure in pregnancy have shown abnormal changes in the brain and the development of ASD like behaviors in the offspring. Currently, research looking at solutions for glyphosate removal is primarily in agriculture but shows that binders such as humic acid can help decrease the anti-microbial effects of glyphosate and improve the health of animals. Since the use of glyphosate is continuing to increase, we need to act in terms of decreasing exposure of our children beginning in utero and finding ways to mitigate its negative effects.

Presenter: ERICA PIERSON, PIERSON ND

Title of Talk: SUPPORTING GALLBLADDER HEALTH IN CHILDREN TO OPTIMIZE DETOXIFICATION

Abstract:

The gallbladder is a crucial organ of detoxification that is often overlooked in children. It is assumed that children have healthy gallbladder function simply because they are children. Physicians are trained to recognize gallbladder issues most often in females who are "fair, fat, female, fertile and forty". The increased toxic load that children experience today combined with their rising rate of obesity and nutrient-deficient food intake warrants recognizing the role that bile function plays in their health. Bile is the major route of excretion of trace metals, particularly arsenic, copper, manganese, lead, mercury, selenium, silver, and zinc as well as mycotoxins and xenobiotics. Supporting bile synthesis and flow, gallbladder contraction and the addition of binders can help support the elimination of toxins within the body. Genetics and nutrients involved in bile synthesis will be discussed as well as those that impact bile viscosity. The physiology of gallbladder contraction including neurotransmitters and hormones will also be reviewed. Lastly, the journey that bile takes through the digestive tract and the important interaction between bile and the microbiome will be reviewed as well. Actionable steps to optimize bile function safely and effectively in children will be included throughout. One in-depth case will be presented to highlight the impact that gallbladder support can have on the overall health and neurodevelopment of a young child.

Presenter: KRISHNA DONIPARTHI, MD

Title of Talk: THE PROCESS AND TREATMENT OF CELLULAR TOXICITY

Abstract:

Background:

Neurological development disorders in children are exponentially rising in the United States due to a complex cascade of toxic events that lead to cellular malfunction.

Aims:

This lecture examines the propensity for toxic burden in the human body and the role that phospholipid, fatty acids, nutrition and supplementation can play in addressing the body's toxic burden.

Methods:

By incorporating evidence from scientific articles, clinical experience, and patient outcomes, this lecture will demonstrate that phospholipid nutrition and supplementation can lower the toxicity of cells and provide a better cell structure from which all other therapies can work and improve patient outcomes.

Presenter: WILLIAM SHAW, PhD

Title of Talk: HPHPA FROM CLOSTRIDIA ALTERS FATTY ACID METABOLISM TO REDUCE THE ACTIVATION OF THE CRITICAL DEVELOPMENTAL PROTEIN SONIC HEDGEHOG TO CAUSE AUTISM

Abstract:

Elevated dopamine metabolites, palmitic acid, dicarboxylic acid metabolites from omega oxidation of fatty acids, and the metabolite 3-hydroxy-(3-hydroxyphenyl)- 3-hydroxypropionic acid (HPHPA) from intestinal Clostridia bacteria have been detected by multiple recent metabolomic studies of urine samples from children with autism throughout the world. Using HPHPA and two additional phenyl metabolites of Clostridia bacteria as diagnostic markers for autism (HPHPA, 3-hydroxyhippuric acid, and 3-hydroxyphenylacetic acid), the Chinese group (Xiong et al.,2016) found that an elevation of these 3 markers had a 98.4 % specificity for the diagnosis of an autism spectrum disorder, a remarkably high number that at least appears to be a significant diagnostic marker for a major subgroup of autism. The mean value of 3-hydroxyhippuric acid was 95 times greater in the urine samples of the group with autism compared to those of normal controls. Furthermore, two independent groups found that a common fatty acid, palmitic acid, is found in elevated amounts in children with autism but not in normal controls. As a matter of fact, palmitic acid was the single marker with the greatest correlation (0.65) to autism severity symptoms based on the Autism Diagnostic Observation Schedule (ADOS). The biochemical pathways relating all of these findings have been elucidated in Shaw’s paper in press and reveal a virtual complete biochemical framework for the elucidation of a major cause of autism and will open up multiple new approaches to the treatment of autism. Because Clostridia bacteria are resistant to glyphosate while most beneficial bacteria are killed by it, Clostridia bacteria proliferate in the GI tract of people eating glyphosate contaminated food.

Presenter: BRI KURCSAK, MS, OTR/L, Pediatric Occupational Therapist

Title of Talk: Breathing and feeding dysfunction contributing to pediatric chronic illness.

Abstract:

Breathing is the most important function of the human body. In conjunction with respiratory function, low tongue positioning and mobility are key indicators contributing to chronic illnesses associated with pediatric patients. "Picky" eating and inconsistent sleep habits are closely related to disordered breathing. This "perfect storm" impacts the digestive microbiome along with regulation of the central nervous system. Attendees will be provided with key factors that may reveal oral habits contributing to sleep dysfunction, non-pathologic pain, and discomfort within the gastrointestinal tract. Nutritional deficiencies and environmental factors along with the previously mentioned, set the stage for potential chronic illnesses in pediatrics.

Medical data indicates functional feeding and adequate breathing are essential components during infancy pertaining to breast/bottle feeding. In many cases, infants are diagnosed with reflux, colic, non-traditional sleep habits, and difficulty regulating by self-soothing resulting in complications which can result in chronic disease. Inadequate diet and selective eating characteristics result in significant nutritional deficiencies exacerbating the gastrointestinal imbalances. This lecture will provide Pediatricians and associated specialties an integrative approach with tools to identify oral dysfunction and tips to improve breathing, eating, sleeping, and pooping!

Presenter: ARMEN NIKOGOSIAN, MD

Title of Talk: THE NEUROBIOLOGY OF SPEECH/APRAXIA AND IT’S IMPACTS ON UTILIZING ALTERNATIVE METHODS OF COMMUNICATION

Abstract:

This presentation will focus on an introduction to the neurobiological pathways of speech including Wernickes and Broca’s areas but will also include the lesser known pathways such as the supplementary motor/sensory cortex as well the connections with cerebellum, eye movement, vestibular system and motor planning. Based on that foundational knowledge we then delve into the neurobiology of Spellers. Introduction to Spelling to Communicate (S2C) / Speller’s Method (SM) and what it is helping our kids to achieve. I will then make the connections between the neurobiology of speech and clinical expression of S2C/SM. This will include the balance between regulation and cognitive demand as well as the role Polyvagal Theory plays in all this. I’ll close with a call to action for all practitioners to inform patients who are non-speakers or unreliable speakers about the communication options available to them.

Presenter: NANCY O'HARA, MD, MPH, FAAP, FMAPS &
MYRIAH HINCHEY, ND, MARY SAINTONGE, M.ED

Title of Talk:
Medically & Aesthetically:
Building or Enhancing Your Functional Medicine Practice

Abstract:

Join Nancy H. O’Hara, MD, MPH, Myriah Hinchey, ND and Mary T. Saintonge, M.Ed, CAGS in discussing all of the aspects of setting up a successful functional medicine practice.

At many of these functional medicine conferences we discuss how to get to the root causes of illness, but we do not often discuss the HOW TO of setting up that practice in an integrative and functional way.

Nancy O’Hara, MD, MPH, FAAP, FMAPS will discuss the medical, legal, practical and functional issues in setting up a practice, all from an allopathic perspective. Who do I consider adding to my practice? What are the legal recommendations? What are the practical ways to do this?

Dr. Hinchey, ND will discuss the practical and functional issues of setting up a practice, selling supplements and setting up other companies from a naturopathic perspective. How do I integrate with my community? How do I sell supplements?

Mary Saintonge, M.Ed., CAGS will discuss the Feng Sui of setting up a practice. First impressions are formed in the first three seconds when walking into a new environment. The senses of sight, smell, sound and touch are on alert and an individual is able to make a judgement based upon that initial view. When you have worked in an office for awhile, you become desensitized to all the different elements that belong in the space and forget to take a fresh look at what has been accumulated and arranged in the work environment.

There are 5 simple steps to creating a more safe, serene and inviting work environment. Detoxing your space can provide benefits for you as well as your patients. Just be open to change, keep a flexible mind and be ready to learn how to remake your space, your practice and the lives of you and your patients.

Presenter: MICHAEL ELICE, MD, FMAPS

Title of Talk: ASSESSMENT IN INTEGRATIVE PEDIATRICS

Abstract:

There is a confusing array of testing available to the integrative physician. In this presentation, we will discuss the integrative assessment in pediatrics—from the history to the subtle interpretation of standard labs to the wide array of non-standard evaluations that are available to the practitioner. By the end of this lecture, you should have a firm understanding of the evaluations that are available and how to use them appropriately to guide your treatment decisions.

Presenter: ARI CALHOUN, ND

Title of Talk: A GENOMICALLY TARGETED APPROACH TO DEVELOPMENTAL DELAYS

Abstract:

Description: Come and learn how you can develop a genomically targeted approach using genomics for children with developmental delays and other neurodevelopmental concerns. In this talk Dr. Ari Calhoun with discuss a 16-month-old boy who presented with gross motor, oral motor, receptive and expressive language and social communication delays and how she was able to use his IntellxxDNA™ genomics to create a precision plan that lead to rapid improvement in symptoms.

Co-sponsored by IntellxxDNA™ and Nutramax™

Presenter: TERESA HOLLER, MS, PA-C

Title of Talk: HERBS THAT EXCEL IN COMPLEX PATIENTS

Abstract:

This presentation is designed to assist practitioners in confidently adding herbal remedies to the arsenal of effective treatment for complex patients, particularly those with neuropsychiatric presentations.

Participants will leave the presentation with the knowledge of simple, safe, and effective treatment options for immediate use for their patients.

Upon completion of Teresa Holler's presentation, participants will be aware of the following:

• The role of biofilm in persistent illness and herbal strategies to address it.
• The pleomorphic nature of Lyme borrelia and the impact of both prescription and herbal antimicrobials on persister forms.
• How to integrate herbs and supplements in the management of mold and mycotoxin illness.

Sponsored by Nutramedix

Presenter: THOMAS A. MOORCROFT, DO

Title of Talk: GLYMPHATIC SYSTEM/BRAIN DETOXIFICATION IN PANS/PANDAS

Abstract:

Join Dr. Tom Moorcroft for this journey to a deeper understanding of the glymphatic system, a recently defined brain-wide paravascular pathway for cerebrospinal fluid (CSF) and interstitial fluid(ISF) exchange, in the context of Pediatric Acute-Onset Neuropsychiatric Syndrome(PANS/PANDAS).

PANS/PANDAS is a treatable cause of sudden behavioral changes in children, including OCD, tics, regression, and restricted eating. Many pathogens to which children are commonly exposed can trigger PANS/PANDAS, such as Streptococcus, Borrelia burgdorferi, Bartonella species, and various viral illnesses. This lecture will stress the importance of understanding the triggers, as well as the autoimmune aspect of PANS/PANDAS, in order to develop integrative treatment protocols and prevent relapses. Typically, treatment necessitates a three-pronged approach, involving antimicrobial treatment, immunomodulatory treatment, and psychotherapeutic treatment.

The glymphatic system plays a crucial role in the brain's detoxification process, aiding in the removal of extracellular proteins and excess fluid. This system operates similarly to the peripheral lymphatic system. Its function can be significantly disrupted by age and trauma, especially through alterations in the aquaporin-4 channels. Such disruptions can lead to accumulation of extra- and intra-cellular protein aggregates such as amyloid β and tau. This system's function is predominantly active during deep sleep. As much as 30% of glymphatic drainage is along the nasal lymphatics, which has additional implications in recurrent streptococcal infections, chronic sinusitis and mold/mycotoxin illness.

This lecture will equip clinicians, school team members, and parents with a deeper understanding of the synergy between PANS/PANDAS and the glymphatic system, which is vital to creating comprehensive and effective treatment plans for affected children.

Presenter: JOHN GAITANIS, MD

Title of Talk: AUTISM, EPILEPSY, AND AGGRESSION: THE SECOND REGRESSION SYNDROME

Abstract:

Autism spectrum disorders (ASD) are accompanied by multiple comorbid conditions. Among the most common are anxiety disorders, sleep disturbances, gastrointestinal disorders, and feeding intolerance. Aggressive behaviors occur in more than half of ASD patients and can result in social isolation and heightened parental stress. Epilepsy is also commonly associated with ASD and adversely impacts cognition and increases medical risk. Accurately predicting epilepsy or aggressive behaviors holds the promise of intervening prior to their onset. Understanding the relationship between autism and epilepsy/aggression, is the first step towards improving treatment approaches. This talk focuses on that relationship, with an emphasis on treatment considerations that will enhance overall wellness and neurological health.

Presenter: JAMES NEUENSCHWANDER, MD, ABIM/AAPS, ABIHM, BCEM/AAPS, FMAPS

Title of Talk: USING ALL THE TOOLS TO IDENTIFY YOUR MOLD TOXIC PATIENTS

Abstract:

We all have those patients in our practice who simply don’t improve despite our best efforts. Whether it is a patient with chronic Lyme, PANS/PANDAS, persistent Epstein-Barr virus, recurrent ear infections, or any other chronic illness, these can be our most difficult patients. In this fast-paced presentation, we will review how to use the tools readily available to you to find those patients whose symptoms are persisting because of a mycotoxin illness. We will use a practical, real-world approach using both testing through your local lab along with some of the far more complex evaluations that are also available to help you rapidly identify those patients that would benefit from mold remediation and treatment. At the end of this presentation, attendees should be able to start implementing these techniques in their offices and find solutions to their most difficult patients.

Presenter: JULIE LOGAN, DC

Title of Talk: RECOVERING YOUR PATIENT FROM TOXIN-INDUCED AUTISM

Abstract:

In this talk, Dr. Logan will present a case study of a patient who recovered from Autism to the extent that he "lost the diagnosis at age 9".

Key contributors to his early regression were mercury toxicity and mold toxin exposure. Dr. Logan will describe the case and the combination of interventions used that led to his ultimate recovery.

Attendees will learn the following:

• The interplay between heavy metal and biotoxin- induced neuroimmune symptoms
• Application/interpretation of available lab testing-both standard and specialty
• Applied detoxification strategies for the pediatric patient
• That sometimes we do win the day!!